Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics
- PMID: 2879757
- DOI: 10.2337/diab.36.3.274
Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics
Abstract
Elevated rates of basal hepatic glucose output (bHGO) are significantly correlated with the fasting serum glucose (FSG) level in subjects with non-insulin-dependent diabetes mellitus (NIDDM). This observation suggests that bHGO is a major determinant of the severity of the diabetic state in these subjects. In addition, basal glucagon levels (bGL) are higher in these diabetics than in control subjects, despite the concurrent basal hyperglycemia and hyperinsulinemia, two factors known to suppress glucagon secretion. Although bGL is responsible for sustaining two-thirds of bHGO in normal humans, its role in sustaining elevated rates of bHGO in NIDDM has not been previously defined. To this end, we have studied 13 normal and 10 NIDDM subjects; mean FSG levels were 90 +/- 2 and 262 +/- 21 mg/dl, respectively (P less than .001). The mean fasting serum insulin and glucagon levels were higher in the diabetics than in the controls: 17 +/- 2 vs. 9 +/- 1 microU/ml (P less than .01) and 208 +/- 37 vs. 104 +/- 15 pg/ml (P less than .01), respectively. On separate days, HGO was assessed isotopically (with 3-[3H]glucose) in the basal state and during infusion of somatostatin (SRIF) (600 micrograms/h) alone and in conjunction with replacement infusions of glucose and insulin. The results demonstrate that bHGO is higher in diabetics than in controls (145 +/- 12 vs. 89 +/- 3 mg X m-2 X min-1, P less than .01); during infusion of SRIF alone, HGO was suppressed by 25% (P less than .05) and 34% (P less than .05) of the basal value in controls and diabetics, respectively; when the studies were repeated with glucose levels held constant at or near the FSG level by the glucose-clamp technique, the pattern and degree of HGO suppression was similar to that obtained by infusion of SRIF alone; during isolated glucagon deficiency (SRIF + insulin, 5 mU X m-2 min-1, with serum glucose maintained at basal level), HGO was suppressed by 71 +/- 8% of the basal value in controls (P less than .001) and by 58 +/- 7% in diabetics (P less than .001); and when isolated glucagon deficiency with similar hyperglycemia was created in control subjects, HGO was suppressed by 87% of the basal value.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Influence of hyperglycemia on insulin's in vivo effects in type II diabetes.J Clin Invest. 1984 Mar;73(3):664-72. doi: 10.1172/JCI111258. J Clin Invest. 1984. PMID: 6368585 Free PMC article.
-
The effects of superphysiologic hyperinsulinemia on glucose and lipid metabolism in glucose-tolerant offspring of patients with non-insulin-dependent diabetes mellitus (NIDDM).Diabetes Res Clin Pract. 1992 Sep;17(3):169-82. doi: 10.1016/0168-8227(92)90092-6. Diabetes Res Clin Pract. 1992. PMID: 1425156
-
Effects of fasting on plasma glucose and prolonged tracer measurement of hepatic glucose output in NIDDM.Diabetes. 1987 Oct;36(10):1187-94. doi: 10.2337/diab.36.10.1187. Diabetes. 1987. PMID: 3308588
-
On the role of the gut in diabetic hyperglucagonaemia.Dan Med J. 2017 Apr;64(4):B5340. Dan Med J. 2017. PMID: 28385175 Review.
-
Mechanisms for hyperglycemia in type II diabetes mellitus: therapeutic implications for sulfonylurea treatment--an update.Am J Med. 1991 Jun 24;90(6A):8S-14S. doi: 10.1016/0002-9343(91)90412-q. Am J Med. 1991. PMID: 1872310 Review.
Cited by
-
Pancreatic α-Cell Dysfunction in Type 2 Diabetes: Old Kids on the Block.Diabetes Metab J. 2015 Feb;39(1):1-9. doi: 10.4093/dmj.2015.39.1.1. Diabetes Metab J. 2015. PMID: 25729706 Free PMC article. Review.
-
A computational systems analysis of factors regulating α cell glucagon secretion.Islets. 2012 Jul-Aug;4(4):262-83. doi: 10.4161/isl.22193. Epub 2012 Jul 1. Islets. 2012. PMID: 23093806 Free PMC article.
-
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.Nat Med. 2015 May;21(5):512-7. doi: 10.1038/nm.3828. Epub 2015 Apr 20. Nat Med. 2015. PMID: 25894829
-
Reducing hyperglucagonaemia in type 2 diabetes using low-dose glibenclamide: Results of the LEGEND-A pilot study.Diabetes Obes Metab. 2022 Aug;24(8):1671-1675. doi: 10.1111/dom.14740. Epub 2022 May 18. Diabetes Obes Metab. 2022. PMID: 35491519 Free PMC article. No abstract available.
-
Hepatitis C virus infection promotes hepatic gluconeogenesis through an NS5A-mediated, FoxO1-dependent pathway.J Virol. 2011 Sep;85(17):8556-68. doi: 10.1128/JVI.00146-11. Epub 2011 Jun 22. J Virol. 2011. PMID: 21697492 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous